C

    Cingulate Inc (CING)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.17
    -0.16 (-2.91%)

    Market Cap: $77.44M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    42%(8/19)
    Avg Surprise
    -12.22%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.55 - $-0.39
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    1
    30d
    EPS Estimate Drift
    90d ago$-0.67-49.3%
    60d ago$-0.53-17.9%
    30d ago$-0.53-17.9%
    7d ago$-0.53-17.9%
    Current$-0.45
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.65
    Range$-0.84 - $-0.50
    4 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.65---
    Sep 26EST
    		-$-0.45---
    Jun 26
    		$-0.45$-0.63+28.57%Beat+58.7%
    Mar 26
    		$-0.95$-0.53-79.25%Miss+8.7%
    Dec 25
    		$-0.84$-1.55+45.81%Beat+77.2%
    Sep 25
    		$-1.35$-0.75-80.00%Miss+26.2%
    Jun 25
    		$-1.09$-0.82-32.93%Miss+80.1%
    Mar 25
    		$-1.04$-0.98-6.12%Miss+94.6%
    Dec 24
    		$-3.68$-2.93-25.60%Miss+52.0%
    Sep 24
    		$-1.83$-2.22+17.57%Beat+97.5%
    Jun 24
    		$-5.47$-4.92-11.18%Miss+96.0%
    Mar 24
    		$-19.20N/A+63.58%Beat+77.1%
    Dec 23
    		$-7.66$-4.86-57.61%Miss-1768.3%
    Sep 23
    		$-72.00$-90.40+20.35%Beat+16.7%
    Jun 23
    		$-136.80$-81.60-67.65%Miss-58.3%
    Mar 23
    		$-84.00$-77.60-8.25%Miss+20.5%
    Dec 22
    		$-0.41$-0.37-10.81%Miss-28.1%
    Sep 22
    		$-86.40$-88.80+2.70%Beat-6160.9%
    Jun 22
    		$-86.40$-139.20+37.93%Beat-24585.7%
    Mar 22
    		$-105.60$-56.40-87.23%Miss-
    Dec 21
    		$-0.32$-0.39+17.95%Beat-
    Sep 21
    		$-1.38$0.00N/AMiss-
    Jun 21
    		$-0.35$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.44EV/EBITDA-0.36x
    Price/FCF-3.26xFCF Yield-30.71%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-198.70%ROIC-75.95%
    Financial Health
    Debt/Equity0.22xInterest Coverage-6.03x
    Current Ratio3.50xQuick Ratio3.50x
    Trading Statistics
    Beta-0.91Avg Volume159.89K
    52-Week High$11.8952-Week Low$3.16

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$5.42
    SMA 20$5.27
    SMA 50$5.03
    SMA 200$5.25
    EMA 10$5.36
    EMA 20$5.26
    EMA 50$5.11
    EMA 200$5.08

    MACD

    Line: 0.13Signal: 0.15Hist: -0.01

    ADX

    ADX: 11.9+DI: 18.6-DI: 22.5

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down4.0
    PSAR$5.93

    Bollinger Bands

    Upper Band$5.75
    Lower Band$4.79
    %B Position1823%(Upper)
    Band Width0.40

    RSI (14-Day)

    Neutral
    49.1

    Momentum Oscillators

    Stoch %K48.9
    Stoch %D58.0
    Williams %R-62.7
    ROC (10d)-0.8%
    Momentum-0.04
    CCI (20d)-29.6
    MFI (14d)48.9

    Volatility Measures

    ATR (14d)$0.32(6.2%)
    StdDev (20d)0.24
    Hist Vol49.3%(High)

    Volume Flow

    VWAP$5.17
    OBV-3.3M
    AD Line-6.5M
    CMF (20d)0.221

    Volume Metrics

    Avg Vol (20d)161.1K
    Vol Ratio1.2x
    VWMA (20d)$5.29

    Pivot Points

    R3$5.69
    R2$5.59
    R1$5.46
    Pivot Point$5.36
    S1$5.22
    S2$5.12
    S3$4.99

    Advanced Oscillators

    TSI15.37
    Ultimate Osc54.0
    KST106.57

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$12.98B$0$0$0N/A$0
    Cost of Revenue$0$0$-419,062$0$0$0$160,302$0$0$0N/A$0
    Gross Profit$0$0$419,062$0$0$0$-160,302$0$0$0N/A$0
    Operating Expenses$5.41M$7.92M$5.59M$6.00M$4.65M$3.71M$6.21M$3.28M$3.21M$2.95M$6.80M$5.75M
    R&D$1.49M$2.18M$2.00M$2.85M$2.70M$2.22M$4.33M$1.43M$1.88M$1.81M$4.98M$3.92M
    SG&A$3.93M$5.74M$3.58M$3.15M$1.95M$1.48M$1.88M$1.85M$1.33M$1.14M$1.81M$1.83M
    Operating Income$-5,414,975$-7,923,222$-5,586,264$-5,995,835$-4,649,974$-3,706,035$-6,208,489$-3,282,087$-3,206,180$-2,948,217$-6,797,151$-5,749,674
    Interest Income$-141,276$-536,837$0$0$-138,761$-96,656$0$0$0$0$0$0
    Interest Expense$455,289$1.39M$1.36M$1.35M$333,287$146,643$0$843,556$3,497$24,260$137,546$229,380
    Income Before Tax$-5,870,264$-9,312,089$-6,272,910$-7,341,062$-4,983,261$-3,852,678$-6,131,979$-4,125,643$-3,209,677$-2,972,477$-6,934,697$-5,979,054
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-5,870,264$-9,312,089$-6,272,910$-7,341,062$-4,983,261$-3,852,678$-6,131,979$-4,125,643$-3,209,677$-2,972,477$-6,934,697$-5,979,054
    EBITDA$-5,630,745$-8,648,505$-5,464,116$-7,367,584$-4,619,352$-3,513,755$-6,048,187$-3,960,236$-3,042,399$-2,784,617$-6,624,826$-5,595,011
    EBIT$-5,728,988$-8,775,252$-5,585,948$-7,341,062$-4,844,500$-3,756,022$-6,208,489$-4,125,643$-3,206,180$-2,948,217$-6,797,151$-5,749,674
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CING

    News

    CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52

    Ascendiant Capital Markets has reduced its target price for CINGULATE INC (CING.O) to $44 from $52. This update reflects a change in the analyst's outlook for the company. The article, sourced from Reuters, was published on August 20, 2026.

    Bitget•8/20/26•
    Bearish

    Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00

    Ascendiant Capital Markets has reduced its price target for Cingulate (NASDAQ:CING) from $52.00 to $44.00, while maintaining a "buy" rating. Despite the lowered target, the consensus among four analysts remains a "Moderate Buy" with an average price target of $24.67. Cingulate recently reported a narrower-than-expected quarterly loss of $0.45 per share, and institutional investors currently hold approximately 41.31% of the company's stock.

    MarketBeat•8/20/26•
    Somewhat-Bearish

    Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent

    Dr. Shane J. Schaffer, CEO of Cingulate Inc. (NASDAQ: CING), explains how a child's ADHD diagnosis frequently leads to parents recognizing similar symptoms in themselves, highlighting ADHD's strong heritability. He discusses how cultural shifts, improved public understanding, and reduced stigma are contributing to increased awareness and self-reflection among adults. Schaffer also notes that advancements in treatment, like Cingulate's potential once-daily medication, aim to provide more consistent symptom control and improve outcomes for entire families across generations.

    International Business Times•8/18/26•
    Bullish

    Cingulate (CING) Stock News & Updates

    This page provides news and updates for Cingulate (CING) stock, detailing clinical, regulatory, intellectual property, and financing developments related to its Precision Timed Release™ drug-delivery platform, with a focus on CTx-1301 for ADHD. Recent news includes Q2 2026 financial results, publications of peer-reviewed data on CTx-1301's pharmacokinetics and Phase 3 trial results, inclusion in the Russell 3000E® Index, and the issuance of a new U.S. patent for CTx-1301. The company also reported receiving a Complete Response Letter from the FDA for CTx-1301, requesting additional CMC information, and outlined its commercial readiness efforts.

    Stock Titan•8/14/26•
    Neutral

    Form 8K Cingulate Inc For: 13 August By Investing.com

    This article reports that Cingulate Inc. filed a Form 8K on August 13. The filing is brief and does not provide specific details about the content of the Form 8K. It notes that the information

    Investing.com Canada•8/13/26•
    Neutral

    Frequently Asked Questions About CING

    Does CING pay dividends?
    Cingulate Inc (CING) does not currently pay a regular dividend.
    What is CING's market cap?
    Cingulate Inc (CING) has a market capitalization of $77.44M with a current stock price of $5.17.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In